Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 84
Filter
1.
Nat Commun ; 10(1): 403, 2019 01 24.
Article in English | MEDLINE | ID: mdl-30679422

ABSTRACT

Albuminuria affects millions of people, and is an independent risk factor for kidney failure, cardiovascular morbidity and death. The key cell that prevents albuminuria is the terminally differentiated glomerular podocyte. Here we report the evolutionary importance of the enzyme Glycogen Synthase Kinase 3 (GSK3) for maintaining podocyte function in mice and the equivalent nephrocyte cell in Drosophila. Developmental deletion of both GSK3 isoforms (α and ß) in murine podocytes causes late neonatal death associated with massive albuminuria and renal failure. Similarly, silencing GSK3 in nephrocytes is developmentally lethal for this cell. Mature genetic or pharmacological podocyte/nephrocyte GSK3 inhibition is also detrimental; producing albuminuric kidney disease in mice and nephrocyte depletion in Drosophila. Mechanistically, GSK3 loss causes differentiated podocytes to re-enter the cell cycle and undergo mitotic catastrophe, modulated via the Hippo pathway but independent of Wnt-ß-catenin. This work clearly identifies GSK3 as a critical regulator of podocyte and hence kidney function.


Subject(s)
Albuminuria/metabolism , Glycogen Synthase Kinase 3/metabolism , Kidney Diseases/metabolism , Kidney/physiology , Podocytes/metabolism , Albuminuria/blood , Albuminuria/pathology , Albuminuria/urine , Animals , Cell Cycle , Cell Line , Disease Models, Animal , Drosophila , Gene Deletion , Gene Silencing , Glycogen Synthase Kinase 3/genetics , Glycogen Synthase Kinase 3 beta/drug effects , Glycogen Synthase Kinase 3 beta/genetics , Glycogen Synthase Kinase 3 beta/metabolism , Hippo Signaling Pathway , Kaplan-Meier Estimate , Kidney/pathology , Kidney Diseases/blood , Kidney Diseases/pathology , Kidney Diseases/urine , Male , Mice , Podocytes/enzymology , Podocytes/pathology , Protein Isoforms/genetics , Protein Isoforms/metabolism , Protein Serine-Threonine Kinases/genetics , Protein Serine-Threonine Kinases/metabolism , Proteomics , Rats, Wistar , Renal Insufficiency , Verteporfin/pharmacology , beta Catenin/metabolism
2.
Apoptosis ; 20(7): 907-20, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25808596

ABSTRACT

Glomerulo-podocytic communication plays an important role in the podocytic injury in IgA nephropathy (IgAN). In this study, we examine the role of podocytic angiotensin II receptor subtype 1 (AT1R) and prorenin receptor (PRR) in podocytic apoptosis in IgAN. Polymeric IgA (pIgA) was isolated from patients with IgAN and healthy controls. Conditioned media were prepared from growth arrested human mesangial cells (HMC) incubated with pIgA from patients with IgAN (IgA-HMC media) or healthy controls (Ctl-HMC media). A human podocyte cell line was used as a model to examine the regulation of the expression of AT1R, PRR, TNF-α and CTGF by IgA-HMC media. Podocytic nephrin expression, annexin V binding and caspase 3 activity were used as the functional readout of podocytic apoptosis. IgA-HMC media had no effect on AngII release by podocytes. IgA-HMC media significantly up-regulated the expression of AT1R and PRR, down-regulated nephrin expression and induced apoptosis in podocytes. Mono-blockade of AT1R, PRR, TNF-α or CTGF partially reduced podocytic apoptosis. IgA-HMC media activated NFκB, notch1 and HEY1 expression by podocytes and dual blockade of AT1R with PRR, or anti-TNF-α with anti-CTGF, effectively rescued the podocytic apoptosis induced by IgA-HMC media. Our data suggests that pIgA-activated HMC up-regulates the expression of AT1R and PRR expression by podocytes and the associated activation of NFκB and notch signalling pathways play an essential role in the podocytic apoptosis induced by glomerulo-podocytic communication in IgAN. Simultaneously targeting the AT1R and PRR could be a potential therapeutic option to reduce the podocytic injury in IgAN.


Subject(s)
Apoptosis , Mesangial Cells/cytology , Podocytes/metabolism , Receptors, Angiotensin/metabolism , Receptors, Cell Surface/metabolism , Asian People , Female , Humans , Immunoglobulin A/metabolism , Male , Mesangial Cells/metabolism , Receptors, Notch/metabolism , Renin-Angiotensin System , Signal Transduction , Prorenin Receptor
3.
Am J Physiol Renal Physiol ; 305(2): F182-8, 2013 Jul 15.
Article in English | MEDLINE | ID: mdl-23698113

ABSTRACT

Podocytes are critically important for maintaining the integrity of the glomerular filtration barrier and preventing albuminuria. Recently, it has become clear that to achieve this, they need to be insulin sensitive and produce an optimal amount of VEGF-A. In other tissues, insulin has been shown to regulate VEGF-A release, but this has not been previously examined in the podocyte. Using in vitro and in vivo approaches, in the present study, we now show that insulin regulates VEGF-A in the podocyte in both mice and humans via the insulin receptor (IR). Insulin directly increased VEGF-A mRNA levels and protein production in conditionally immortalized wild-type human and murine podocytes. Furthermore, when podocytes were rendered insulin resistant in vitro (using stable short hairpin RNA knockdown of the IR) or in vivo (using transgenic podocyte-specific IR knockout mice), podocyte VEGF-A production was impaired. Importantly, in vivo, this occurs before the development of any podocyte damage due to podocyte insulin resistance. Modulation of VEGF-A by insulin in the podocyte may be another important factor in the development of glomerular disease associated with conditions in which insulin signaling to the podocyte is deranged.


Subject(s)
Insulin/metabolism , Podocytes/metabolism , Vascular Endothelial Growth Factor A/metabolism , Animals , Humans , Insulin Resistance , Mice , Mice, Knockout , RNA, Messenger/metabolism
4.
J Pathol ; 230(1): 95-106, 2013 May.
Article in English | MEDLINE | ID: mdl-23299523

ABSTRACT

Podocytes are crucial for preventing the passage of albumin into the urine and, when lost, are associated with the development of albuminuria, renal failure and cardiovascular disease. Podocytes have limited capacity to regenerate, therefore pro-survival mechanisms are critically important. Insulin-like growth factor-II (IGF-II) is a potent survival and growth factor; however, its major function is thought to be in prenatal development, when circulating levels are high. IGF-II has only previously been reported to continue to be expressed in discrete regions of the brain into adulthood in rodents, with systemic levels being undetectable. Using conditionally immortalized human and ex vivo adult mouse cells of the glomerulus, we demonstrated the podocyte to be the major glomerular source and target of IGF-II; it signals to this cell via the IGF-I receptor via the PI3 kinase and MAPK pathways. Functionally, a reduction in IGF signalling causes podocyte cell death in vitro and glomerular disease in vivo in an aged IGF-II transgenic mouse that produces approximately 60% of IGF-II due to a lack of the P2 promoter of this gene. Collectively, this work reveals the fundamental importance of IGF-II in the mature podocyte for glomerular health across mammalian species.


Subject(s)
Insulin-Like Growth Factor II/metabolism , Podocytes/cytology , Podocytes/metabolism , Signal Transduction/physiology , Aging/physiology , Animals , Cell Line, Transformed , Cell Survival/physiology , Humans , Insulin-Like Growth Factor I/genetics , Insulin-Like Growth Factor I/metabolism , Insulin-Like Growth Factor II/genetics , Kidney Glomerulus/cytology , Kidney Glomerulus/physiology , Mesangial Cells/cytology , Mesangial Cells/metabolism , Mice , Mice, Transgenic , RNA, Small Interfering/genetics
5.
Am J Physiol Renal Physiol ; 302(12): F1630-9, 2012 Jun 15.
Article in English | MEDLINE | ID: mdl-22419694

ABSTRACT

Endothelial cells in different microvascular segments of the kidney have diverse functions and exhibit differential responsiveness to disease stimuli. The responsible molecular mechanisms are largely unknown. We previously showed that during hemorrhagic shock, VCAM-1 protein was expressed primarily in extraglomerular compartments of the kidney, while E-selectin protein was highly induced in glomeruli only (van Meurs M, Wulfert FM, Knol AJ, de Haes A, Houwertjes M, Aarts LPHJ, Molema G. Shock 29: 291-299, 2008). Here, we investigated the molecular control of expression of these endothelial cell adhesion molecules in mouse models of renal inflammation. Microvascular segment-specific responses to the induction of anti-glomerular basement membrane (anti-GBM), glomerulonephritis and systemic TNF-α treatment showed that E-selectin expression was transcriptionally regulated, with high E-selectin mRNA and protein levels preferentially expressed in the glomerular compartment. In contrast, VCAM-1 mRNA expression was increased in both arterioles and glomeruli, while VCAM-1 protein expression was limited in the glomeruli. These high VCAM-1 mRNA/low VCAM-1 protein levels were accompanied by high local microRNA (miR)-126 and Egfl7 levels, as well as higher Ets1 levels compared with arteriolar expression levels. Using miR-reporter constructs, the functional activity of miR-126 in glomerular endothelial cells could be demonstrated. Moreover, in vivo knockdown of miR-126 function unleashed VCAM-1 protein expression in the glomeruli upon inflammatory challenge. These data imply that miR-126 has a major role in the segmental, heterogenic response of renal microvascular endothelial cells to systemic inflammatory stimuli.


Subject(s)
Glomerulonephritis/metabolism , Inflammation/metabolism , Kidney/metabolism , MicroRNAs/metabolism , Vascular Cell Adhesion Molecule-1/metabolism , Animals , Cell Line , Cells, Cultured , Disease Models, Animal , E-Selectin/genetics , E-Selectin/metabolism , Endothelial Cells/metabolism , Endothelium, Vascular/cytology , Endothelium, Vascular/metabolism , Glomerulonephritis/genetics , Humans , Inflammation/genetics , Kidney Glomerulus/metabolism , Mice , MicroRNAs/genetics , Tumor Necrosis Factor-alpha/pharmacology , Vascular Cell Adhesion Molecule-1/genetics
6.
Am J Physiol Renal Physiol ; 300(1): F40-8, 2011 Jan.
Article in English | MEDLINE | ID: mdl-20980411

ABSTRACT

The endothelial glycocalyx is a gel-like layer which covers the luminal side of blood vessels. The glomerular endothelial cell (GEnC) glycocalyx is composed of proteoglycan core proteins, glycosaminoglycan (GAG) chains, and sialoglycoproteins and has been shown to contribute to the selective sieving action of the glomerular capillary wall. Damage to the systemic endothelial glycocalyx has recently been associated with the onset of albuminuria in diabetics. In this study, we analyze the effects of high glucose on the biochemical structure of the GEnC glycocalyx and quantify functional changes in its protein-restrictive action. We used conditionally immortalized human GEnC. Proteoglycans were analyzed by Western blotting and indirect immunofluorescence. Biosynthesis of GAG was analyzed by radiolabeling and quantified by anion exchange chromatography. FITC-albumin was used to analyze macromolecular passage across GEnC monolayers using an established in vitro model. We observed a marked reduction in the biosynthesis of GAG by the GEnC under high-glucose conditions. Further analysis confirmed specific reduction in heparan sulfate GAG. Expression of proteoglycan core proteins remained unchanged. There was also a significant increase in the passage of albumin across GEnC monolayers under high-glucose conditions without affecting interendothelial junctions. These results reproduce changes in GEnC barrier properties caused by enzymatic removal of heparan sulfate from the GEnC glycocalyx. They provide direct evidence of high glucose-induced alterations in the GEnC glycocalyx and demonstrate changes to its function as a protein-restrictive layer, thus implicating glycocalyx damage in the pathogenesis of proteinuria in diabetes.


Subject(s)
Glucose/administration & dosage , Glycocalyx/metabolism , Kidney Glomerulus/drug effects , Cells, Cultured , Endothelial Cells/drug effects , Glucose/pharmacology , Glycocalyx/ultrastructure , Glycosaminoglycans/biosynthesis , Heparan Sulfate Proteoglycans/biosynthesis , Humans , Kidney Glomerulus/cytology , Kidney Glomerulus/physiopathology
7.
Am J Physiol Renal Physiol ; 299(3): F664-73, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20630938

ABSTRACT

Human immunodeficiency virus (HIV)-1 has been demonstrated to contribute to the pathogenesis of HIV-associated nephropathy. In renal biopsy studies, podocytes have been reported to be infected by HIV-1. However, the mechanism involved in HIV-1 internalization into podocytes is not clear. In the present study, we evaluated the occurrence of HIV-1 internalization into conditionally immortalized human podocytes and the mechanism involved. Human podocytes rapidly internalized R5 and X4 HIV-1 primary strains via an endocytosis-dependent pathway, without establishing a productive infection. The HIV-1 internalization was dendritic cell-specific ICAM-3-grabbing nonintegrin (DC-SIGN) receptor mediated. The role of DC-SIGN was confirmed by using specific blocking antibodies and transfection with small interfering (si) RNA/DC-SIGN. Since podocyte HIV-1 trafficking was not altered by pH-modulating agents, it appeared that HIV-1 routing occurred through nonacid vesicular compartments. Interestingly, transfection of podocytes with neither siRNA/caveolin-1 nor siRNA/clathrin heavy chain inhibited podocyte viral accumulation. Thus it appears that clathrin-coated vesicles and caveosomes may not be contributing to HIV-1-associated membrane traffic.


Subject(s)
Cell Adhesion Molecules/physiology , HIV-1/physiology , Lectins, C-Type/physiology , Podocytes/virology , Receptors, Cell Surface/physiology , Virus Internalization , Caveolin 1/genetics , Cells, Cultured , Clathrin/genetics , Endocytosis/physiology , Humans , Hydrogen-Ion Concentration , Podocytes/cytology , RNA, Small Interfering/genetics , Transfection
8.
Clin Exp Immunol ; 158(1): 143-53, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19737241

ABSTRACT

Myeloperoxidase (MPO)-anti-neutrophil cytoplasmic autoantibody (ANCA)-associated necrotizing crescentic glomerulonephritis (NCGN) is characterized by abundant leucocyte infiltration. Chemokines are chemotactic cytokines involved in receptor-mediated recruitment of leucocytes. Our objective was to analyse spatiotemporal gene expression of chemokines and chemokine receptors in anti-MPO-mediated NCGN, to find potential targets for intervening with leucocyte influx. NCGN was induced in mice by co-administration of anti-MPO immunoglobulin (Ig)G and lipopolysaccharide. mRNA expression levels of chemokines and chemokine receptors were analysed in whole kidney lysates as well as in laser microdissected glomeruli and tubulo-interstitial tissue 1 and 7 day(s) after NCGN induction. Several chemokines and chemokine receptors were induced or up-regulated in anti-MPO-mediated NCGN, both on day 1 (chemokines CCL3, 5; CXCL2, 5, 13; receptor CXCR2) and on day 7 (chemokines CCL2, 5, 7, 8, 17, 20; CXCL1, 2, 5, 10; CX(3)CL1; receptors CCR2, 8; CX(3)CR1). The expression levels of most chemokines and receptors were higher in glomeruli than in the tubulo-interstitium. Because of the temporal induction of CXCR2 on day 1, we hypothesized CXCR2 as a potential target for treatment in anti-MPO-induced NCGN. Inhibition of CXCR2 using a goat-anti-CXCR2 serum prior to NCGN induction increased glomerular neutrophil influx but did not affect crescent formation and albuminuria. In conclusion, expression levels of various chemokines and chemokine receptors were increased in anti-MPO NCGN, and expressed particularly in glomeruli. These chemokines and receptors may serve as potential targets for treatment. Inhibition of a single target, CXCR2, did not attenuate anti-MPO NCGN. Combinatorial interventions may be necessary to avoid redundancy.


Subject(s)
Chemokines/genetics , Gene Expression Regulation , Glomerulonephritis/immunology , Kidney Glomerulus/immunology , Receptors, Chemokine/genetics , Animals , Antibodies, Antineutrophil Cytoplasmic/immunology , Chemokine CXCL1/genetics , Chemokine CXCL2/genetics , Chemokine CXCL5/genetics , Endothelial Cells/immunology , Endothelial Cells/metabolism , Female , Gene Expression , Glomerulonephritis/metabolism , Immune Sera/pharmacology , Immunoglobulin G/pharmacology , Kidney Glomerulus/metabolism , Kidney Tubules/immunology , Kidney Tubules/metabolism , Lipopolysaccharides/pharmacology , Mice , Mice, Inbred C57BL , Mice, Knockout , Models, Animal , Neutrophils/immunology , Neutrophils/metabolism , Peroxidase/immunology , Receptors, Interleukin-8B/immunology , Time Factors
9.
Diabetologia ; 52(9): 1944-52, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19533082

ABSTRACT

AIMS/HYPOTHESIS: Peroxisome proliferator-activated receptor (PPAR) gamma agonists are used increasingly in the treatment of type 2 diabetes. In the context of renal disease, PPARgamma agonists reduce microalbuminuria in diabetic nephropathy; however, the mechanisms underlying this effect are unknown. Glomerular podocytes are newly characterised insulin-sensitive cells and there is good evidence that they are targeted in diabetic nephropathy. In this study we investigated the functional and molecular effects of the PPARgamma agonist rosiglitazone on human podocytes. METHODS: Conditionally immortalised human podocytes were cultured with rosiglitazone and functional effects were measured with glucose-uptake assays. The effect of rosiglitazone on glucose uptake was also measured in 3T3-L1 adipocytes, nephrin-deficient podocytes, human glomerular endothelial cells, proximal tubular cells and podocytes treated with the NEFA palmitate. The role of the glucose transporter GLUT1 was investigated with immunofluorescence and small interfering RNA knockdown and the plasma membrane expression of GLUT1 was determined with bis-mannose photolabelling. RESULTS: Rosiglitazone significantly increased glucose uptake in wild-type podocytes and this was associated with translocation of GLUT1 to the plasma membrane. This effect was blocked with GLUT1 small interfering RNA. Nephrin-deficient podocytes, glomerular endothelial cells and proximal tubular cells did not increase glucose uptake in response to either insulin or rosiglitazone. Furthermore, rosiglitazone significantly increased basal and insulin-stimulated glucose uptake when podocytes were treated with the NEFA palmitate. CONCLUSIONS/INTERPRETATION: In conclusion, rosiglitazone has a direct and protective effect on glucose uptake in wild-type human podocytes. This represents a novel mechanism by which PPARgamma agonists may improve podocyte function in diabetic nephropathy.


Subject(s)
Glucose Transporter Type 1/metabolism , Glucose/metabolism , Hypoglycemic Agents/pharmacology , Kidney Glomerulus/metabolism , Podocytes/metabolism , Thiazolidinediones/pharmacology , Biological Transport/drug effects , Cell Culture Techniques , Cell Line , Cell Membrane/drug effects , Cell Membrane/metabolism , DNA Primers , Glucose Transporter Type 1/drug effects , Glucose Transporter Type 1/genetics , Humans , Kidney Glomerulus/drug effects , Kinetics , Podocytes/drug effects , RNA/genetics , Rosiglitazone , Transfection
10.
Trop Doct ; 37(4): 267-8, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17988510

ABSTRACT

Cardiac failure is a common medical presentation in Uganda. This study primarily focuses on the aetiology of heart failure in 65 adult patients and assesses the utility of echocardiography in a resource-limited setting. Our findings suggest that endomyocardial fibrosis is much less prevalent than previously described in other regions of Uganda and highlights the need for more basic descriptive studies on common presenting illnesses in rural Africa.


Subject(s)
Heart Failure/diagnostic imaging , Adolescent , Adult , Aged , Aged, 80 and over , Echocardiography , Endomyocardial Fibrosis/complications , Heart Failure/etiology , Heart Valve Diseases/complications , Humans , Middle Aged , Radiography , Uganda
11.
Diabetologia ; 50(7): 1423-32, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17476476

ABSTRACT

AIMS/HYPOTHESIS: Rapamycin, part of the immunosuppressive regimen of the Edmonton protocol, has been shown to inhibit vascular endothelial growth factor (VEGF) production and VEGF-mediated survival signalling in tumour cell lines. This study investigates the survival-promoting activities of VEGF in human islets and the effects of rapamycin on islet viability. MATERIALS AND METHODS: Levels of VEGF and its receptors in isolated human islets and whole pancreas was determined by western blotting and immunostaining. Islet viability following VEGF or immunosuppressive drug treatment was determined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Islet VEGF release was measured by ELISA. Mouse islets infected with an adenovirus expressing the gene for VEGF were transplanted syngeneically into streptozotocin-induced diabetic mice, with blood glucose levels measured three times per week. RESULTS: Isolated human islets produced multiple isoforms of VEGF and VEGF receptors 1, 2 and 3 and the coreceptor neuropilin 1. Exogenous VEGF (10 ng/ml) prevented human islet death induced by serum starvation, which suggests that VEGF can act as a survival factor for human islets. Transplantation of mouse islets infected with a VEGF-expressing adenovirus in a syngeneic model, improved glycaemic control at day 1 post-transplantation (p < 0.05). Rapamycin at 10 and 100 ng/ml significantly reduced islet VEGF release (by 37 +/- 4% and 43 +/- 6%, respectively; p < 0.05) and at 100 ng/ml reduced islet viability (by 36 +/- 9%) and insulin release (by 47 +/- 7%, all vs vehicle-treated controls; p < 0.05). Tacrolimus had no effect on islet VEGF release or viability. CONCLUSIONS/INTERPRETATION: Our data suggest that rapamycin may have deleterious effects on islet survival post-transplantation, both through a direct effect on islet viability and indirectly through blockade of VEGF-mediated revascularisation.


Subject(s)
Immunosuppressive Agents/pharmacology , Islets of Langerhans/pathology , Neoplasms/mortality , Vascular Endothelial Growth Factor A/metabolism , Animals , Cell Survival , Cells, Cultured , Humans , Islets of Langerhans/cytology , Islets of Langerhans/metabolism , Islets of Langerhans Transplantation , Mice , Mice, Inbred C57BL , Neoplasms/pathology , Neovascularization, Pathologic , Receptors, Vascular Endothelial Growth Factor/metabolism , Signal Transduction , Sirolimus/pharmacology
12.
Clin Exp Immunol ; 148(2): 368-72, 2007 May.
Article in English | MEDLINE | ID: mdl-17437424

ABSTRACT

Systemic administration of islet-derived antigens has been shown to protect against diabetes in the non-obese diabetic (NOD) mouse by the induction of antigen-specific regulatory T cells. Bystander regulation to related and unrelated islet-derived antigens (intramolecular and intermolecular recognition) in this context is recognized. We tested if intranasal administration of glutamic acid decarboxylase 65 (GAD 65)-derived peptides could protect against both autoimmune and, through bystander regulation, alloimmune responses in a NOD mouse model. Spontaneously diabetic female NOD mice underwent islet transplantation from either C57Bl/6 or NOD islet donors. Islet recipients were treated with intranasal GAD 65-derived peptides or control (ovalbumin) peptide pre- and post-transplantation. In-vitro analysis of the effect of inhalation was defined using lymph node proliferation assays and supernatant analysis for cytokines. GAD 65-derived peptide inhalation resulted in significant protection against recurrent autoimmune disease, with the generation of an interleukin (IL)-10-producing immune phenotype in a syngeneic islet transplant model. This phenotype, however, was not robust enough to protect against alloimmune responses. Inhalation of GAD-derived peptides induces an immunoregulatory response that protects against recurrent autoimmune, but not alloimmune responses in the NOD mouse.


Subject(s)
Autoimmune Diseases/prevention & control , Diabetes Mellitus, Experimental/prevention & control , Glutamate Decarboxylase/therapeutic use , Isoenzymes/therapeutic use , Administration, Inhalation , Animals , Autoimmune Diseases/immunology , Bystander Effect/drug effects , Diabetes Mellitus, Experimental/immunology , Female , Interleukin-10/biosynthesis , Islets of Langerhans Transplantation , Mice , Mice, Inbred NOD , Peptide Fragments/therapeutic use , Recurrence , Survival Analysis
13.
Kidney Int ; 71(6): 569-73, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17228362

ABSTRACT

Acute renal disease is common in sub-Saharan Africa, with high mortality. Its etiology is poorly understood; quartan malaria owing to Plasmodium malariae was implicated in previous series. Few previous studies have included histological data; furthermore, much of the literature pre-dates the human immunodeficiency virus (HIV) epidemic. We report prospective analysis of acute proteinuric renal disease in children in rural Uganda. Clinical and laboratory data are presented on 65 patients (aged 2-14 years, mean 8.4; 35 male, 30 female) in 41 of whom histological diagnosis was obtained by renal biopsy. The most frequent histological finding was endocapillary proliferative glomerulonephritis (GN) in 27/41 cases, in 20 of which eosinophils were very prominent. No cases showed features of HIV nephropathy. Malarial films were positive in 11 cases: all owing to Plasmodium falciparum. Patients were treated with diuretics, antihypertensives, and supportive measures. Corticosteroids were rarely used, being reserved for patients with minimal changes on renal biopsy. Clinical outcomes were fair: 91% of patients survived to discharge. We conclude that acute GN is common in children in Uganda, that an unusual eosinophilic proliferative GN is the most frequent histological finding, that HIV is not implicated as an important factor in this age group, and that good outcomes can be achieved using simple clinical and laboratory diagnostic methods. Renal biopsy in selected cases is feasible and helpful, especially in allowing rational use of corticosteroids and other potentially toxic treatments. Symptomatic treatments and careful supportive care will allow the majority of children to recover.


Subject(s)
Eosinophils/pathology , Glomerulonephritis/epidemiology , Glomerulonephritis/pathology , Adolescent , Biopsy , Child , Child, Preschool , Eosinophilia/diagnosis , Eosinophilia/epidemiology , Eosinophilia/pathology , Female , Glomerulonephritis/diagnosis , Humans , Kidney Glomerulus/pathology , Male , Prevalence , Prospective Studies , Uganda/epidemiology
14.
Diabetologia ; 50(1): 26-31, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17131141

ABSTRACT

AIMS/HYPOTHESIS: Anaemia is a common complication of renal impairment. It has been suggested that renal failure secondary to diabetes is associated with more severe anaemia, but this has not been clearly substantiated in the published literature. To clarify this, we undertook a single centre, retrospective study to identify the impact of diabetes on anaemia associated with renal impairment. MATERIALS AND METHODS: Information on clinical, biochemical and haematological parameters of 2,052 stable ambulatory patients attending a single tertiary referral renal unit was collected. The impact of diabetic kidney disease on haemoglobin levels at all degrees of renal impairment was studied by comparison with patients with non-diabetic kidney disease after correcting for other commonly associated variables that influence anaemia in patients with renal impairment. RESULTS: Linear regression analysis showed lower haemoglobin in patients with diabetic kidney disease (p < 0.01). At chronic kidney disease (CKD) stages 3, 4 and 5, mean haemoglobin levels in patients with diabetic kidney disease compared with those in patients with non-diabetic kidney disease were 129.5 vs 136.9 g/l (p < 0.001), 120.5 vs 126.9 g/l (p < 0.001) and 107.1 vs 115.9 g/l (p < 0.01), respectively. At CKD stage 4 and 5 the two groups were comparable for ferritin, plasma intact parathyroid hormone levels, ACE inhibitor use and length of follow-up by a nephrologist. CONCLUSIONS/INTERPRETATION: Diabetic kidney disease is associated with lower haemoglobin in comparison with non-diabetic kidney disease, especially at GFR <60 ml/min.


Subject(s)
Anemia/etiology , Diabetes Mellitus/blood , Diabetic Nephropathies/blood , Hemoglobins/metabolism , Anemia/drug therapy , Anemia/physiopathology , Diabetes Mellitus/physiopathology , Diabetic Nephropathies/complications , Diabetic Nephropathies/physiopathology , Disease Progression , Erythropoietin/therapeutic use , Female , Humans , Kidney Diseases/blood , Kidney Diseases/complications , Kidney Diseases/physiopathology , Male , Middle Aged , Regression Analysis , Retrospective Studies
15.
Kidney Int ; 70(6): 1038-45, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16837924

ABSTRACT

Glucocorticoids are widely used in the treatment of human glomerular diseases, but their mode of action is poorly understood particularly in steroid-sensitive nephrotic syndrome, which is most common in childhood and is characterized by a lack of inflammation in the kidney. The podocyte is a key cell in the glomerulus in health and disease: until recently, human podocytes have been difficult to study in vitro. We have developed a conditionally immortalized human podocyte cell line transfected with a temperature-sensitive simian virus 40 transgene: when the transgene is inactivated in vitro, these cells adopt the phenotype of differentiated podocytes. We have used these cells to evaluate, using immunocytochemistry, reverse transcriptase-polymerase chain reaction, and Western blotting, direct effects of the glucocorticoid dexamethasone at concentrations designed to mimic in vivo therapeutic corticosteroid levels. Dexamethasone upregulated expression of nephrin and tubulin-alpha, and downregulated vascular endothelial growth factor. Effects on cell cycle were complex with downregulation of cyclin kinase inhibitor p21 and augmentation of podocyte survival, without any effect on apoptosis. We report cytokine production by human podocytes, especially interleukin (IL)-6 and -8; IL-6 expression was suppressed by dexamethasone. These potent direct effects on podocytes illustrate a novel mode of action of glucocorticoids and suggest potential new therapeutic strategies for glomerular disease.


Subject(s)
Antigens, Polyomavirus Transforming , Dexamethasone/pharmacology , Glucocorticoids/pharmacology , Podocytes/drug effects , Simian virus 40/immunology , Cell Line, Transformed , Cell Survival/drug effects , Cell Transformation, Viral , Child, Preschool , Cyclin-Dependent Kinase Inhibitor p21/metabolism , Dose-Response Relationship, Drug , Gene Expression Regulation/drug effects , Humans , Immunohistochemistry , Interleukin-6/metabolism , Membrane Proteins/metabolism , Tubulin/metabolism , Vascular Endothelial Growth Factor A/metabolism
16.
Am J Physiol Renal Physiol ; 291(4): F722-30, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16622173

ABSTRACT

Proteoglycans (PGs) are important for the glomerular barrier, for cell signaling, and for the anchorage of cells to the glomerular basement membrane. They are, however, complex macromolecules, and their production has not yet been thoroughly investigated in podocytes. In the present study, we studied the biosynthesis of PGs by highly differentiated human podocytes and in rats. The cells were treated with puromycin aminonucleoside (PAN; a nephrosis-inducing agent), steroids (used as primary treatment for nephrotic syndrome), or both. Analysis was made by TaqMan real-time PCR, Western blotting, and by metabolic labeling with (35)S and (3)H. We found that podocytes produce versican, syndecan-1, decorin, and biglycan together with the previously known PG syndecan-4, glypican, and perlecan. PAN treatment downregulated the mRNA and the protein expression of both versican (by 24 +/- 6%, P < 0.01, for mRNA and by 50% for protein) and perlecan (by 14 +/- 5%, P < 0.05, for mRNA and by 50% for protein). The decreased expression was confirmed by studying the glomerular gene expression in rats treated with PAN during a time course study. In addition, puromycin decreased the expression of enzymes involved in the glycosaminoglycan biosynthesis. Steroid treatment decreased perlecan (by 24 +/- 3%, P < 0.01) and syndecan-1 expression (by 30 +/- 4%, P < 0.01) but increased the expression of decorin 2.5-fold. The observed alterations of PG synthesis induced by PAN may lead to decreased glomerular anionic charge and disturbed podocyte morphology, factors that are important for the development of a nephrotic syndrome.


Subject(s)
Nephrotic Syndrome/physiopathology , Podocytes/physiology , Proteoglycans/biosynthesis , Animals , Cell Line , DNA Primers , DNA Probes , Dexamethasone/pharmacology , Female , Glycosaminoglycans/genetics , Podocytes/drug effects , Proteoglycans/genetics , Puromycin Aminonucleoside/pharmacology , Rats , Rats, Sprague-Dawley
17.
Kidney Int ; 69(9): 1633-40, 2006 May.
Article in English | MEDLINE | ID: mdl-16557232

ABSTRACT

Glomerular endothelial cells (GEnC) are specialized cells with important roles in physiological filtration and glomerular disease. Despite their unique features, GEnC have been little studied because of difficulty in maintaining them in cell culture. We have addressed this problem by generation of conditionally immortalized (ci) human GEnC using technology with which we have previously produced ci podocytes. Primary culture GEnC were transduced with temperature-sensitive simian virus 40 large tumour antigen and telomerase using retroviral vectors. Cells were selected, cloned, and then characterized by light and electron microscopy (EM), response to vascular endothelial growth factor (VEGF), and tumour necrosis factor (TNF)alpha, expression of endothelial markers by focused gene array, immunofluorescence and Western blotting, and formation and behaviour of monolayers. CiGEnC proliferated at the permissive temperature (33 degrees C) and became growth arrested at the non-permissive temperature (37 degrees C). CiGEnC retained morphological features of early-passage primary culture GEnC up to at least p41, confirming successful immortalization. EM demonstrated fenestrations, increased in number by VEGF. mRNA analysis confirmed expression of the endothelial markers platelet endothelial cell adhesion molecule 1, intercellular adhesion molecule 2, VEGF receptor 2, and von Willebrand factor, validated by immunofluorescence and Western blotting. CiGEnC also expressed Tie2, and TNFalpha upregulated E-selectin. CiGEnC formed monolayers with barrier properties responsive to cyclic adenosine 3',5' monophosphate (cAMP) and thrombin. CiGEnC retain the markers and behaviour of primary culture GEnC. They express fenestrations which are upregulated in response to VEGF. These cells are a unique resource for further study of GEnC and their roles in glomerular filtration, glomerular disease, and response to glomerular injury.


Subject(s)
Cell Line, Transformed , Endothelial Cells/ultrastructure , Kidney Glomerulus/cytology , Vascular Endothelial Growth Factor A/pharmacology , Biomarkers , Cell Adhesion Molecules/genetics , Cyclic AMP/pharmacology , Electric Impedance , Endothelial Cells/drug effects , Endothelial Cells/physiology , Gene Expression , Humans , Kidney Glomerulus/drug effects , Kidney Glomerulus/physiology , Oligonucleotide Array Sequence Analysis , RNA, Messenger/analysis , RNA, Messenger/metabolism , Simian virus 40/genetics , Thrombin/pharmacology , Vascular Endothelial Growth Factor Receptor-2/genetics , von Willebrand Factor/genetics
18.
Am J Physiol Renal Physiol ; 291(1): F196-207, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16525158

ABSTRACT

Vascular endothelial growth factor (VEGF)-A is an autocrine survival factor for podocytes, which express two VEGF receptors, VEGF-R1 and VEGF-R3. As VEGF-A is not a known ligand for VEGF-R3, the aim of this investigation was to examine whether VEGF-C, a known ligand for VEGF-R3, served a function in podocyte biology and whether this was VEGF-R3 dependent. VEGF-C protein expression was localized to podocytes in contrast to VEGF-D, which was expressed in parietal epithelial cells. Intracellular calcium ([Ca2+]i) experiments demonstrated that VEGF-C induced a 0.74+/-0.09-fold reduction in [Ca2+]i compared with baseline in human conditionally immortalized podocytes (hCIPs; P<0.05, one sample t-test, n=8). Cytotoxicity experiments revealed that in hCIPs VEGF-C reduced cytotoxicity to 81.4+/-1.9% of serum-starved conditions (P<0.001, paired t-test, n=16), similar to VEGF-A (82.8+/-4.5% of serum-starved conditions, P<0.05, paired t-test). MAZ51 (a VEGF-R3 kinase inhibitor) inhibited the VEGF-C-induced reduction in cytotoxicity (106.2+/-2.1% of serum-starved conditions), whereas MAZ51 by itself had no cytotoxic effects on hCIPs. VEGF-C was also shown to induce a 0.5+/-0.13-fold reduction in levels of MAPK phosphorylation compared with VEGF-A and VEGF-A-Mab treatment (P<0.05, ANOVA, n=4), yet had no effect on Akt phosphorylation. Surprisingly, immunoprecipitation studies detected no VEGF-C-induced autophosphorylation of VEGF-R3 in hCIPs but did so in HMVECs. Moreover, SU-5416, a tyrosine kinase inhibitor, blocked the VEGF-C-induced reduction in cytotoxicity (106+/-2.8% of serum-starved conditions) at concentrations specific for VEGF-R1. Together, these results suggest for the first time that VEGF-C acts in an autocrine manner in cultured podocytes to promote survival, although the receptor or receptor complex activated has yet to be elucidated.


Subject(s)
Cell Survival/drug effects , Cell Survival/physiology , Podocytes/drug effects , Podocytes/physiology , Vascular Endothelial Growth Factor C/physiology , Calcium/analysis , Calcium/metabolism , Cell Line , Endothelial Cells/chemistry , Endothelial Cells/cytology , Endothelial Cells/drug effects , Endothelial Cells/physiology , Humans , Immunoprecipitation , Indoles/pharmacology , Kidney Glomerulus/chemistry , Mitogen-Activated Protein Kinase Kinases/analysis , Mitogen-Activated Protein Kinase Kinases/physiology , Naphthalenes/pharmacology , Phosphorylation , Podocytes/chemistry , Podocytes/cytology , Protein Kinase Inhibitors/pharmacology , Proto-Oncogene Proteins c-akt/analysis , Proto-Oncogene Proteins c-akt/physiology , Pyrroles/pharmacology , Receptors, Vascular Endothelial Growth Factor/analysis , Receptors, Vascular Endothelial Growth Factor/physiology , Signal Transduction/drug effects , Signal Transduction/physiology , Vascular Endothelial Growth Factor A/analysis , Vascular Endothelial Growth Factor A/physiology , Vascular Endothelial Growth Factor D/analysis , Vascular Endothelial Growth Factor D/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...